The importance of the nucleocytoplasmic transport machinery as a potential target in cancer therapy is supported by a previously described global enhancement of nuclear transport upon malignant transformation [37] and already exemplified by specific inhibitors of the nuclear export protein Crm1 (Chromosome region maintenance 1 protein homolog). Here, XPO1 is linked to cancer.